Keywords
essential hypertension
hemostasis
thrombodynamics
hemodynamic and oscillatory indices
Full Text
Abstract
Aim: to study the relationship between blood level of «youth protein» GDF11 and hemostatic parameters in healthy people and hypertensive patients.
Materials and methods. We examined 102 women: 30 relatively healthy women (group 1); 37 women with hypertensive disease (HD) who received antihypertensive therapy (group 2); 35 women with HD who received antihypertensive therapy and regular courses of kinesitherapy (group 3).
Results. In hypertensive women, there were no significant deviations in platelets number, values of activated partial thromboplastin time, prothrombin and thrombin times, fibrinogen concentration, but the rate of formation and size of fibrin clot were significantly increased that was the evidence of significant hypercoagulation. At the same time in patients with HD signifi- cant changes in hemodynamic and oscillatory indices were revealed that illustrated the disorders of axial and parietal blood flow. In patients with GB who received antihypertensive therapy and regular courses of kinesitherapy (over the time of 2–3 years) we found normalization of blood pressure, also thrombodynamic and hemodynamic parameters approached to normal.
Conclusion. In women with HD who received antihypertensive therapy blood content of «youth protein» GDF11 was significantly reduced. Numerous positive and negative correlations between the level of GDF11, hemostatic parameters, blood pressure and hemodynamic and oscillatory indices that characterized axial and parietal blood flow were revealed in patients with GB.
REFERENCES
1. Lo redo F.S., Steinhauser M.L., Jay S.M. et al. Growth Di erentiation Factor 11 Is a Circulating Factor that Reverses Age-Related Cardiac Hypertrophy. Cell. 2013; 153 (4): 828–39.
2. Poggioli T., Vujic A., Yang P. Circulating Growth Di erentiation Factor 11/8 Levels Decline With Age. Circ Res. 2016; 118 (1): 29–37.
3. Olson K.A., Beatty A.L., Heidecker B. et al. Association of growth dif- ferentiation factor 11/8, putative antiageing factor, with cardiovascu- lar outcomes and overall mortality in humans: analysis of the Heart and Soul and HUNT3 cohorts. Eur Heart J. 2015; 36 (48): 3426–34.
4. Barkagan Z.S., Momot A.P. Diagnosis and controlled therapy of the hemostasis system [Diagnostika i kontroliruemaya terapiya sistemy gemostaza]. Moskva: N’yudiamed. 2008: 289 s (in Russ.).
5. Panteleev M.A., Balandina A.N., Soshitova N.P. et al. Spatial dynam- ics of hemostasis and thrombosis: theory and practice [Prostranst- vennaya dinamika gemostaza i tromboza: teoriya i praktika]. Trom- boz, gemostaz i reologiya. 2010; 4: 48–60 (in Russ.).
6. Fine I., Kuznik B., Kaminsky A. et al. New noninvasive index for eval- uation of the vascular age of healthy and sick people. J Biomed Opt. 2012; 17 (8): 2–7.
7. Fine I., Kaminsky A.V., Shenkman L. A new sensor for stress mea- surement based on blood ow uctuations. In: Dynamics and Fluc- tuations in Biomedical Photonics XII [Ed. V.V. Tuchin]. SPIE Press. 2016; 9707: 970705.
8. Panchenko E.P., Dobrovolsky A.B. rombosis in cardiology. Mecha- nisms of development and the possibility of therapy [Trombozy v kar- diologii. Mekhanizmy razvitiya i vozmozhnosti terapii]. Moskva: Sport i kul’tura. 1999: 462 s (in Russ.).
9. Bokarev IN, Popova LV, Kozlova Т.V. romboses and antithrombot- ic therapy in clinical practice [Trombozy i protivotromboticheskaya terapiya v klinicheskoj praktike]. Moskva: MIA. 2009: 512 s (in Russ.).
10. Wu F., Wang H.Y., Cai F. et al. Valsartan decreases platelet activity and arterial thrombotic events in elderly patients with hypertension. Chin Med J (Engl). 2015; 128 (2): 153–8.
11. Keskin A., Tombuloglu M., Buyukkececi F. Fibrinolytic activity and platelet release reaction in essential hypertension. Jpn Heart J. 1994; 35 (6): 757–63.
12. Kuznik B.I., Bogdanov I.G., Isakova N.V. et al. e thrombodynam- ic properties of arterial and venous blood in patients with IHD in the preoperative and early postoperative periods with coronary bypass surgery [Trombodinamicheskie svojstva arterial’noj i venoznoj krovi u bol’nyh IBS v dooperacionnom i rannem posleoperacionnom periodah pri vypolnenii koronarnogo shuntirovaniya]. Patologicheska- ya ziologiya i eksperimental’naya terapiya. 2015; 1: 39–45 (in Russ.).
13. Lipets E., Vlasova O., Urnova E. et al. Circulating Contact-Pathway- Activating Microparticles Together with Factors IXa and XIa Induce Spontaneous Clotting in Plasma of Hematology and Cardiologic Patients. PloS One. 2014; 9 (1): e87692.
14. Aukrust P., Halvorsen B., Yndestad A. et al. Chemokines and cardio- vascular risk. Arterioscler romb Vasc Biol. 2008; 28: 1909–19.
15. Wolf S.I., Howat S., Abraham D.J. et al. Agonistic anti-ICAM-1 antibodies in scleroderma: activation of endothelial pro-in ammatory cascades. Vas- cul Pharmacol. 2013; 59 (1–2): 19–26. DOI: 10.1016/j.vph.2013.05.002.
16. Arends S.J., Damoiseaux J.G., Duijvestijn A.M. et al. Function- al implications of IgG anti-endothelial cell antibodies in pulmonary arterial hypertension. Autoimmunity. 2013; 46 (7): 463–70. DOI: 10.1183/09031936.00164209.
17. Kuznik B.I., Davydov S.O., Stepanov A.V., Morar N.V. Change in the concentration of irisin in the blood of patients with essential hypertension after physical exertion [Izmenenie koncentracii irisina v krovi bol’nyh gipertonicheskoj bolezn’yu posle zicheskoj nagruzki]. Kardi- ologiya. 2017; 57 (4): 77–8 (in Russ.).
18. Moriel P., Sevanian A., Ajzen A. Nitric oxide, cholesterol oxides and endothelium-dependent vasodilation in plasma of patients with essen- tial hypertension. Braz J Med Bio Res. 2002; 35 (11): 1301–9.
19. Kuznik B.I. Cellular and molecular mechanisms of hemostasis regu- lation in norm and in pathology: monograph [Kletochnye i moleku- lyarnye mekhanizmy regulyacii sistemy gemostaza v norme i pri patolo- gii: monogra ya]. Chita: Ekspress-izdatel’stvo. 2010: 832 s (in Russ.).
20. Witkowski Yu.A., Kuznik B.I., Govorin A.V. et al. e system of hemostasis, leukocyte-platelet relationships, acute phase proteins, in ammatory cytokines in patients with various forms of coronary heart disease [Sistema gemostaza, lejkocitarno-trombocitarnye vzaimootnosheniya, belki ostroj fazy, vospalitel’nye citokiny u bol’nyh s razlichnymi formami ishemicheskoj bolezni serdca]. Tromboz, gemostaz, reologi- ya. 2009; 1: 49–63 (in Russ.).
21. Roitman E.V. Clinical hemorheology [Klinicheskaya gemoreologiya]. Tromboz, gemostaz i reologiya. 2003; 3: 13–27 (in Russ.).
22. Muraviev A.V., Tikhomirova I.A., Oslyakova A.O. et al. Evaluation of hemorheological status and microcirculation in healthy individuals and patients with hypertensive disease [Ocenka gemoreologicheskogo statusa i sostoyanie mikrocirkulyacii u zdorovyh lic i bol’nyh gipertonicheskkoj bolezn’yu]. Regionarnoe krovoobrashchenie i mikrocirku- lyaciya. 2009; 3: 37–42 (in Russ.).
23. Medvedev I.N. Microrheological parameters of erythrocytes in arte- rial hypertension and dyslipidemia in the context of complex hypolipidemic action [Mikroreologicheskie parametry eritrocitov pri arterial’nojgipertonii i dislipidemii na fone kompleksnogo gipolipid- emicheskogo vozdejstviya]. Rossijskij kardiologicheskij zhurnal. 2017; 4: 13–7 (in Russ.).
24. Ushakov A.V., Ivanchenko V.S., Gagarina A.A. Features of the pro le of blood pressure and heart rate variability in patients with arterial hyper- tension, depending on the level of physical activity and psychoemotion- al stress [Osobennosti pro lya arterial’nogo davleniya i variabel’nosti serdechnogo ritma u bol’nyh arterial’noj gipertenziej v zavisimosti ot urovnya zicheskoj aktivnosti i psihoehmocional’nogo napryazheniya]. Rossijskij kardiologicheskij zhurnal. 2017; 4: 23–8 (in Russ.).
25. Khavinson V. Kh., Kuznik B.I., Tarnovskaya S.I. et al. GDF11 Pro- tein as a Geroprotector. Biology Bulletin Reviews. 2016; 6 (2): 141–8.
26. Williams G., Zentar M.P., Gajendra S. et al. Transcriptional basis for the inhibition of neural stem cell proliferation and migration by the TGF β-family member GDF11. PloS One. 2013; 8 (11): e78478.
27. Khavinson V. Kh., Kuznik BI, Ryzhak G.A. et al. «Old age protein» CCL11, «youth protein» GDF11 and their role in the age-related pathol- ogy [«Belok starosti» CCL11, «belok molodosti» GDF11 i ih rol› v voz- ractnoj patologii]. Uspekhi gerontologii. 2016; 29 (5): 722–31 (in Russ.).